Cargando…

Targeted Therapy in Melanoma and Mechanisms of Resistance

The common mutation BRAFV600 in primary melanomas activates the mitogen-activated protein kinase/extracellular-signal-regulated kinase (MAPK/ERK) pathway and the introduction of proto-oncogene B-Raf (BRAF) and mitogen-activated protein kinase kinase (MEK) inhibitors (BRAFi and MEKi) was a breakthrou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Czarnecka, Anna M., Bartnik, Ewa, Fiedorowicz, Michał, Rutkowski, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369697/ https://www.ncbi.nlm.nih.gov/pubmed/32605090 http://dx.doi.org/10.3390/ijms21134576

Ejemplares similares

Molecular Biology of Osteosarcoma
por: Czarnecka, Anna M., et al.
Publicado: (2020)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

Triple combinations of immunotherapy and targeted therapy in patients with melanoma with brain metastases
por: Rutkowski, Piotr, et al.
Publicado: (2023)

Management Strategies for Adults with Locally Advanced, Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa): Challenges and Solutions
por: Czarnecka, Anna M, et al.
Publicado: (2023)

Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies
por: Stachyra, Karolina, et al.
Publicado: (2021)

Neoadjuvant Treatment Options in Soft Tissue Sarcomas
por: Spałek, Mateusz Jacek, et al.
Publicado: (2020)

Myocarditis Induced by Immunotherapy in Metastatic Melanoma—Review of Literature and Current Guidelines
por: Czarnecka, Anna M., et al.
Publicado: (2022)

Chondrosarcoma-from Molecular Pathology to Novel Therapies
por: Zając, Agnieszka E., et al.
Publicado: (2021)

The Role of the Mitochondrial Genome in Ageing and Carcinogenesis
por: Czarnecka, Anna M., et al.
Publicado: (2011)

Choosing The Right Animal Model for Renal Cancer Research()
por: Sobczuk, Paweł, et al.
Publicado: (2020)

The Long-Term Outcomes of Intensive Combined Therapy of Adult Patients with Localised Synovial Sarcoma
por: Kozak, Katarzyna, et al.
Publicado: (2020)

New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma
por: Bilmin, Krzysztof, et al.
Publicado: (2021)

Imaging of Uveal Melanoma—Current Standard and Methods in Development
por: Solnik, Małgorzata, et al.
Publicado: (2022)

Mutation profile of primary subungual melanomas in Caucasians
por: Borkowska, Aneta, et al.
Publicado: (2020)

Thyroid Hormones as Renal Cell Cancer Regulators
por: Szymański, Łukasz, et al.
Publicado: (2016)

Choosing the right cell line for renal cell cancer research
por: Brodaczewska, Klaudia K., et al.
Publicado: (2016)

Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted Therapies
por: Rubanov, Andrey, et al.
Publicado: (2022)

The Role of Macrophages in Sarcoma Tumor Microenvironment and Treatment
por: Zając, Agnieszka E., et al.
Publicado: (2023)

Clinicopathological Features and Prognostic Factors of Primary Acral Melanomas in Caucasians
por: Borkowska, Aneta M., et al.
Publicado: (2020)

Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies
por: Pizzimenti, Stefania, et al.
Publicado: (2021)

Current approaches in identification and isolation of human renal cell carcinoma cancer stem cells
por: Khan, Mohammed I., et al.
Publicado: (2015)

Resistance to Molecularly Targeted Therapies in Melanoma
por: Patel, Meet, et al.
Publicado: (2021)

Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF (V600) Mutation-Positive Melanoma
por: Czarnecka, Anna M., et al.
Publicado: (2021)

Epithelioid Sarcoma—From Genetics to Clinical Practice
por: Czarnecka, Anna M., et al.
Publicado: (2020)

Biological Heterogeneity of Chondrosarcoma: From (Epi) Genetics through Stemness and Deregulated Signaling to Immunophenotype
por: Zając, Agnieszka, et al.
Publicado: (2021)

Follow-up in melanoma patients
por: Rutkowski, Piotr, et al.
Publicado: (2014)

Biology of renal tumour cancer stem cells applied in medicine
por: Matak, Damian, et al.
Publicado: (2015)

The role of the cell–cell interactions in cancer progression
por: Kamińska, Katarzyna, et al.
Publicado: (2015)

Epigenetic Abnormalities in Chondrosarcoma
por: Bereza, Michał, et al.
Publicado: (2023)

MicroRNAs in melanoma development and resistance to target therapy
por: Fattore, Luigi, et al.
Publicado: (2017)

Optical coherence tomography (OCT) with 2 nm axial resolution using a compact laser plasma soft X-ray source
por: Wachulak, Przemysław, et al.
Publicado: (2018)

Vitamin D receptor gene polymorphisms in breast and renal cancer: Current state and future approaches
por: KHAN, MOHAMMED I., et al.
Publicado: (2013)

Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
por: Rogala, Paweł, et al.
Publicado: (2022)

Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors
por: Fenton, Sarah E., et al.
Publicado: (2019)

Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
por: Piejko, Karolina, et al.
Publicado: (2023)

p53 Family in Resistance to Targeted Therapy of Melanoma
por: Vlašić, Ignacija, et al.
Publicado: (2022)

Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Follicular Differentiation
por: Płachta, Iga, et al.
Publicado: (2021)

Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation
por: Płachta, Iga, et al.
Publicado: (2021)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

Surgery of Primary Melanomas
por: Rutkowski, Piotr, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_ol9b0obshnrsdam8uoigdsrq87